Reboxetine, a Selective Norepinephrine Reuptake Inhibitor, Is an Effective and Well-Tolerated Treatment for Panic Disorder
The DOI matches its Crossref record.
Abstract
BACKGROUND: Tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) as well as benzodiazepines have been shown to be effective for the treatment of panic disorder. The introduction of SSRIs has enabled a greater understanding of the role of serotonin in the etiology of panic disorder; however, the role of norepinephrine has been more challenging to ascertain. The aim of this study was to determine the efficacy and tolerability of reboxetine, a novel selective norepinephrine reuptake inhibitor, in patients with panic disorder with and without agoraphobia. METHOD: Eighty-two patients (aged 18-65 years) with DSM-III-R panic disorder, with or without agoraphobia, were randomly assigned to receive 6 to 8 mg/day of reboxetine (42 patients) or placebo (40 patients) for 8 weeks in this placebo-controlled, parallel-group, double-blind clinical trial. RESULTS: Of the 82 patients enrolled in the trial, 75 were considered in the analysis (37 patients in the reboxetine group and 38 patients in the placebo group). At last assessment, there was a significant reduction in the mean number of panic attacks (range, 9.3-1.2) and phobic symptoms (range, 8.1-3.2) in the reboxetine group compared with the placebo group (ranges, 8.5-5.8 and 7.7-5.2, respectively; p < .05). Improvement in Hamilton Rating Scale for Depression, Hopkins Symptom Checklist-90, and Sheehan Disability Scale scores were also greater in the reboxetine group compared with the placebo group. Adverse events reported more frequently with reboxetine than placebo included dry mouth (36% vs. 16%), constipation (27% vs. 22%), and insomnia (26% vs. 22%). CONCLUSION: Reboxetine was effective and well tolerated in the treatment of panic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Role of brain norepinephrine in the behavioral response to stress
Morilak, D. A., Barrera, G., Echevarria, D. J., Garcia, A. S., Hernandez, A., Ma, S., & Petre, C. O. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.007 · Cited by 570
Drug effects on salivary glands: dry mouth
Scully CBE, C. (2003) · Oral Diseases · doi:10.1034/j.1601-0825.2003.03967.x · Cited by 472
Sheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467
Mitte, K. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.05.003 · Cited by 396
A dverse D rug R eactions in the O rofacial R egion
Scully, C., & Bagan, J.-V. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500405 · Cited by 254
Morilak, D. A., & Frazer, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004080 · Cited by 252
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00002 · Cited by 112
Murphy, S. E., Yiend, J., Lester, K. J., Cowen, P. J., & Harmer, C. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009164 · Cited by 90
Evidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Bondi, C. O., Barrera, G., Lapiz, M. D. S., Bedard, T., Mahan, A., & Morilak, D. A. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.11.015 · Cited by 56
Dannon, P. N., Iancu, I., & Grunhaus, L. (2002) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.421 · Cited by 41
“The results presented in this study support those of a previous placebo-controlled study of panic disorder with and without agoraphobia (n¼ 82) were treated for 8 weeks with reboxetine (6–8 mg/day) (Versiani et al., 2000, 2002).”
BackgroundMethodPringle, A., McCabe, C., Cowen, P., & Harmer, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112474523 · Cited by 37
Cohen-Yavin, I., Yoran-Hegesh, R., Strous, R. D., Kotler, M., Weizman, A., & Spivak, B. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318183796d · Cited by 16
Metadata
- Authors
- Versiani, M., Cassano, G., Perugi, G., Benedetti, A., Mastalli, L., Nardi, A., & Savino, M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-01-15
- Volume
- 63
- Issue
- 1
- Pages
- 31-37
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2994249241
- Cited by
- 140
- References
- 0
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.